ERBB2 and neoplasm: In the Human Epidermal Growth Factor Receptor 2 positive (HER2+) tumor model (MMTV-neu), MTD and MCT achieved similar efficacy by reducing the tumor growth to ~50% (mean relative volumes being 2 and 1.8 respectively) of the Vehicle-treated tumors at the end of treatment on Day 28 (mean relative volume 3.7) (Fig. 1a, left).